The pharmaceutical company's consolidated net profit rose to 10.87 billion rupees ($131.3 million) in the quarter ended June 30, compared with 5.18 billion rupees a year earlier.

Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.

Zydus has seen a steady growth in its U.S. business, led by new product launches including cancer treatment drug gRevlimid and anti-convulsant medicine gTrokendi.

The Ahmedabad-based drugmaker reported a more than 57% rise in total revenue from operations. Its earnings before interest, taxes, depreciation and amortisation margin improved to 29.3% from 20.5% last year.

Last week, Zydus Wellness, a unit focused on making consumer wellness products such as energy drink Glucon D, posted a nearly 19% dip in its first-quarter net profit.

Last month, Dr Reddy's Laboratories and Cipla reported first-quarter profits above estimates on the back of strong sales in domestic and overseas markets.

Shares of Zydus Lifesciences rose as much as 1.3% after the results before paring the gains. The stock has climbed nearly 55% so far this year, outperforming a nearly 22% rise in the broader Nifty pharma index.

($1 = 82.7750 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Subhranshu Sahu)